In the recent phase III MORPHO trial by Levis et al., 356 patients with FLT3-ITD AML underwent alloSCT and were either assigned to a maintenance treatment with Gilteritinib or placebo over a period of two years. This evidence concerns the gene FLT3 and acute myeloid leukemia.